Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$4.82 - $7.7 $169,182 - $270,270
-35,100 Reduced 27.69%
91,659 $486,000
Q1 2022

May 13, 2022

BUY
$6.0 - $16.98 $7,446 - $21,072
1,241 Added 0.99%
126,759 $830,000
Q4 2021

Feb 11, 2022

BUY
$15.19 - $29.33 $484,211 - $934,952
31,877 Added 34.04%
125,518 $2.06 Million
Q2 2021

Aug 11, 2021

SELL
$26.5 - $38.23 $827,409 - $1.19 Million
-31,223 Reduced 25.01%
93,641 $3.25 Million
Q1 2021

May 13, 2021

BUY
$29.83 - $56.81 $3.15 Million - $6 Million
105,639 Added 549.49%
124,864 $3.94 Million
Q4 2020

Feb 16, 2021

BUY
$39.12 - $54.99 $178,465 - $250,864
4,562 Added 31.11%
19,225 $909,000
Q3 2020

Nov 12, 2020

SELL
$29.21 - $46.58 $339,566 - $541,492
-11,625 Reduced 44.22%
14,663 $682,000
Q2 2020

Aug 13, 2020

BUY
$33.67 - $40.0 $326,060 - $387,360
9,684 Added 58.32%
26,288 $948,000
Q1 2020

May 14, 2020

SELL
$24.28 - $49.8 $425,045 - $871,798
-17,506 Reduced 51.32%
16,604 $589,000
Q4 2019

Feb 14, 2020

BUY
$24.84 - $45.46 $847,292 - $1.55 Million
34,110 New
34,110 $1.55 Million
Q3 2019

Nov 14, 2019

SELL
$22.78 - $29.08 $392,431 - $500,961
-17,227 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$15.0 - $22.49 $196,095 - $294,011
-13,073 Reduced 43.15%
17,227 $378,000
Q1 2019

May 15, 2019

BUY
$14.02 - $16.74 $232,732 - $277,884
16,600 Added 121.17%
30,300 $490,000
Q4 2018

Feb 14, 2019

SELL
$10.95 - $15.44 $51,475 - $72,583
-4,701 Reduced 25.55%
13,700 $201,000
Q3 2018

Nov 14, 2018

SELL
$12.21 - $16.61 $280,182 - $381,149
-22,947 Reduced 55.5%
18,401 $288,000
Q2 2018

Aug 14, 2018

BUY
$11.13 - $21.86 $460,203 - $903,867
41,348 New
41,348 $611,000

Others Institutions Holding ZYME

About Zymeworks Inc.


  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $685M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.